We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Quality assessment of first-trimester screening for preterm pre-eclampsia.
- Authors
Dhaifalah, I.; Magalova, E.; Studnykova, D.; Havalova, J.; Slintakova, E.; Cuckle, H.
- Abstract
<bold>Objective: </bold>To assess the performance and impact of first-trimester preterm pre-eclampsia screening in a single center.<bold>Methods: </bold>This was a single-center study of women with a singleton pregnancy who were screened prospectively for preterm pre-eclampsia (i.e. delivery before 37 weeks' gestation) using maternal characteristics, mean arterial pressure (MAP), uterine artery Doppler pulsatility index, maternal serum pregnancy-associated plasma protein-A and placental growth factor. The individual risk for preterm pre-eclampsia was estimated from a published model, and those with a risk above 1 in 200 were recommended to take 150 mg soluble aspirin per day until 34 weeks. Information on the incidence of pre-eclampsia was obtained from the hospital register of adverse pregnancy outcomes. Screening performance indicators, including detection and false-positive rates, were estimated from the distribution of risks. Screening impact was estimated by dividing the observed prevalence by the expected prevalence, which was derived from the distribution of risks.<bold>Results: </bold>The distributions of MAP, uterine artery Doppler pulsatility index and serum markers were consistent with the risk model parameters. The estimated detection and false-positive rates were 79.7% and 16.2%, respectively. There were six cases of preterm pre-eclampsia, four of which occurred in women with a positive screening result. The prevalence was 62% of that expected, but the 95% CI of 23-140% indicated that the study was underpowered to assess the impact.<bold>Conclusions: </bold>This study demonstrates that the performance of preterm pre-eclampsia screening can be estimated in a single center with fewer than 2000 women screened. However, in order to assess the impact of screening on the prevalence of the condition, a much larger cohort is needed. © 2022 International Society of Ultrasound in Obstetrics and Gynecology.
- Subjects
ECLAMPSIA; PREECLAMPSIA; PLACENTAL growth factor; PREGNANCY outcomes; UTERINE artery; BIOMARKERS; RISK assessment; QUESTIONNAIRES; ARTERIES; FERRANS &; Powers Quality of Life Index; PHYSICS; FIRST trimester of pregnancy; IMPACT of Event Scale
- Publication
Ultrasound in Obstetrics & Gynecology, 2022, Vol 60, Issue 6, p746
- ISSN
0960-7692
- Publication type
journal article
- DOI
10.1002/uog.24956